I thought the royalty flow alone on MAB deals could have accounted for a nice chunk of the MEDX valuation. So I was in agreement with you, they shouldn't have sold out so low. My impression of medx was the ceo was fairly disengaged. Perhaps that contributed to cashing out so soon.
SGEN is the most Medarex like play I can think of.